Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Receivables: 2020-2022

Historic Change in Receivables for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Mar 2022 value amounting to -$47,000.

  • 4D Molecular Therapeutics' Change in Receivables rose 90.98% to -$47,000 in Q1 2022 from the same period last year, while for Mar 2022 it was -$965,000, marking a year-over-year decrease of 1222.09%. This contributed to the annual value of -$47,000 for FY2022, which is 96.73% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Change in Receivables of -$47,000 as of Q1 2022, which was up 93.68% from -$744,000 recorded in Q4 2021.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Receivables ranged from a high of $590,000 in Q4 2020 and a low of -$744,000 during Q4 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Change in Receivables averaged around -$108,667, with its median value being -$99,000 (2020).
  • Examining YoY changes over the last 5 years, 4D Molecular Therapeutics' Change in Receivables showed a top increase of 267.55% in 2021 and a maximum decrease of 426.26% in 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' Change in Receivables (Quarterly) stood at $590,000 in 2020, then tumbled by 226.10% to -$744,000 in 2021, then skyrocketed by 90.98% to -$47,000 in 2022.
  • Its Change in Receivables was -$47,000 in Q1 2022, compared to -$744,000 in Q4 2021 and -$427,000 in Q3 2021.